Screener
TG Therapeutics TGTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Lease liability – current portion | 1,913 | 1,044 |
| Deferred revenue - current portion | 16,825 | 21,234 |
| Accrued compensation | 35,205 | 21,850 |
| Total current liabilities | 268,493 | 153,760 |
| Deferred revenue, non-current portion | 14,525 | 8,807 |
| Loan payable – non-current | 745,387 | 245,645 |
| Lease liability – non-current | 7,141 | 7,021 |
| Total liabilities | $1,035,546 | $415,233 |
Document
FAQ
- What is TG Therapeutics's total current liabilities?
- TG Therapeutics (TGTX) reported total current liabilities of $268.49M in Q2 2026.
- How has TG Therapeutics's total current liabilities changed year-over-year?
- TG Therapeutics's total current liabilities increased by 56.2% year-over-year, from $171.89M to $268.49M.
- What is the long-term trend for TG Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), TG Therapeutics's total current liabilities has grown at a 11.9% compound annual growth rate (CAGR), from $87.55M to $153.76M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about TG Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude